Related Experiment Videos

Soluble syndecan-1 (CD138): is it useful as a prognostic factor in Korean patients with multiple myeloma?

¹Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.

The Korean Journal of Hematology

|December 2, 2010

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.

British journal of haematology·2026

Development of Genetically Modified ARH-77 Feeder Cells for Efficient Expansion of Natural Killer Cells with Potent Anti-Tumor Activity.

Cancers·2026

The prognostic factors and immune microenvironment of primary plasma cell leukemia: the KMMWP-2204 study.

Haematologica·2026

Randomized Phase II Study of Bortezomib, Lenalidomide, and Dexamethasone (VRD) Versus Lenalidomide and Dexamethasone (RD) in Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM1910).

Cancer research and treatment·2026

Overcoming resistance in CD44-overexpressing myeloma through combination therapy with ATRA, bortezomib, and NK cells.

Cancer immunology, immunotherapy : CII·2026

Aerosolized Pentamidine Is an Effective Prophylaxis for Pneumocystis jiroveci Pneumonia in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation.

Journal of Korean medical science·2026

See all related articles